Cargando…
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic and seasonal influenza and thus could have the potential to broaden vaccine efficacy. We developed OVX836, a recomb...
Autores principales: | Del Campo, Judith, Pizzorno, Andres, Djebali, Sophia, Bouley, Julien, Haller, Marjorie, Pérez-Vargas, Jimena, Lina, Bruno, Boivin, Guy, Hamelin, Marie-Eve, Nicolas, Florence, Le Vert, Alexandre, Leverrier, Yann, Rosa-Calatrava, Manuel, Marvel, Jacqueline, Hill, Fergal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344521/ https://www.ncbi.nlm.nih.gov/pubmed/30701093 http://dx.doi.org/10.1038/s41541-019-0098-4 |
Ejemplares similares
-
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza
por: Del Campo, Judith, et al.
Publicado: (2021) -
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022) -
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results( )
por: Withanage, Kanchanamala, et al.
Publicado: (2021) -
372. Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical trial
por: Willems, Paul, et al.
Publicado: (2023) -
Antigen specific activation of cytotoxic CD8(+) T cells by Staphylococcus aureus infected dendritic cells
por: Friot, Adèle, et al.
Publicado: (2023)